retatrutide phase 2 trial obesity nejm 2023 The that put “24%” on the map Phase 2 Trial of Retatrutide

Liver Fat (MASLD) A Phase 2 trial showed retatrutide reduced liver fat by 82%

Like liraglutide, gastrointestinal symptoms were the most common side effects, though generally well-tolerated

It is safe, soothing, and unlikely to cause harm, and it may create a better skin environment for healing, but it should not be expected to remove stretch marks on its own

This comprehensive assessment will determine if you meet the medical criteria for these prescription medications

This tailored approach not only enhances the effectiveness of the medication but also creates a nurturing environment that is essential for long-term success